Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 496 to 510 of 720 results for pain management

  1. Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

    Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 August 2014
    View recommendations

    Sections for TA320

  2. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA768

  3. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA460

  4. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153

  5. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  6. Pilon fractures: In adults with closed pilon fractures, what method of fixation provides the best clinical and cost effectiveness outcomes as assessed by function and incidence of major complications at 2 years (stratified for timing of definitive surgery early [under 36 hours] versus later [over 36 hours])?

    the injury can lead to long‑term disability, most commonly arthritis with pain and stiffness. Surgery can improve outcomes, allowing...

    Research recommendation
    Published
    12 December 2022

  7. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

    Technology appraisal guidance
    Published
    25 August 2004
    View recommendations

    Sections for TA82

  8. Pilon fractures:- In adults with closed pilon fractures, what method of fixation provides the best clinical and cost effectiveness outcomes as assessed by function and incidence of major complications at 2 years (stratified for timing of definitive surgery early [under 36 hours] versus later [over 36 hours])?

    the injury can lead to long-term disability, most commonly arthritis with pain and stiffness. Surgery can improve outcomes, allowing...

    Research recommendation
    Published
    21 March 2016

  9. Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)

    Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA426

  10. Irreversible electroporation for treating pancreatic cancer (HTG437)

    Evidence-based recommendations on irreversible electroporation for treating pancreatic cancer. This involves inserting special needles into the tumour in the pancreas and using short electrical pulses to destroy the cancer cells.

    HealthTech guidance
    Published
    3 May 2017
    View recommendations

    Sections for HTG437

  11. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA1018)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in adults.

    Technology appraisal guidance
    Published
    20 November 2024
    View recommendations

    Sections for TA1018

  12. What is the clinical and cost effectiveness of alternative treatments as firstline treatment for trigeminal neuralgia compared with other better-tolerated pharmacological treatments?

    guidance details Comes from guidance Neuropathic pain in adults: pharmacological management in non-specialist settings...

    Research recommendation
    Published
    26 October 2020

  13. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

    Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.

    Technology appraisal guidance
    Published
    23 October 2024
    View recommendations

    Sections for TA1010

  14. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    2 June 2015
    View recommendations

    Sections for TA343

  15. Ultrasound in monitoring:- What is the clinical and cost effectiveness of using ultrasound to monitor disease in adults with RA when clinical examination is inconclusive or inconsistent with other signs of disease activity?

    inflammatory condition that needs regular review to enable adjustments in management to achieve a target of remission or low disease...

    Research recommendation
    Published
    11 December 2018